Tempest Therapeutics, Inc.
NCM: TPSTLive Quote
About Tempest Therapeutics, Inc.
Healthcare
Biotechnology
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
📊 Fundamental Analysis
Tempest Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -203.6%, which indicates that capital utilization is currently under pressure.
At a current price of $2.05, TPST currently trades near the bottom of its 52-week range (5%), indicating potential value or weakness (Range: $1.50 - $12.23).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$18.80M
Trailing P/E
--
Forward P/E
-1.69
Beta (5Y)
-1.89
52W High
$12.23
52W Low
$1.50
Avg Volume
178K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App